Skip to content
Bored Studies
RecruitingPhase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Eli Lilly and Company · NCT07353931

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
900
US sites recruiting
38
Study start
February 9, 2026
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

Being studied: Eloralintide; Placebo

Conditions: Osteoarthritis; Overweight or Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening
  • Have a stable body weight (less than 5% body weight change) for 90 days prior to screening
  • Have tried at least once to lose weight through diet but were unsuccessful
  • Have osteoarthritis of the knee and at least one of the following conditions:
  • Be over 50 years old
  • Have morning knee stiffness that lasts about 30 minutes
  • Have a crackling or grinding sound or feeling in the knee

Exclusion Criteria

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Have an active knee infection
  • Have had within 90 days prior to screening:
  • heart attack
  • stroke
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Recruiting US locations

  • AMR Clinical

    Mobile, AL 36608

    Site contact: 251-414-1984

  • Care Access - 801 South Power Road, Mesa

    Mesa, AZ 85206

    Site contact: 877-791-0656

  • Elite Pain and Spine Institute - South Crimson Road

    Mesa, AZ 85209

    Site contact: Zeeshan Malik

  • Elite Clinical Studies, LLC

    Phoenix, AZ 85018

    Site contact: 602-788-3437

  • Tucson Orthopaedic Institute - North Wyatt Drive

    Tucson, AZ 85712

    Site contact: 520-404-0276

  • Ark Clinical Research - Fountain Valley

    Fountain Valley, CA 92708

    Site contact: 714-988-2021

  • Wolverine Clinical Trials

    Santa Ana, CA 92706

    Site contact: 714-617-2426

  • Encompass Clinical Research

    Spring Valley, CA 91978

    Site contact: 619-660-9068

  • Diablo Clinical Research, Inc.

    Walnut Creek, CA 94598

    Site contact: 925-930-7267

  • Skylight Health Research - Colorado Springs

    Colorado Springs, CO 80917

    Site contact: Renee Flick

  • Westside Center for Clinical Research

    Jacksonville, FL 32205

    Site contact: 904-693-1490

  • Care Access - St. Petersburg

    St. Petersburg, FL 33710

    Site contact: 877-791-0656

  • Conquest Research

    Winter Park, FL 32789

    Site contact: 407-916-0060

  • Orita Clinical Research

    Decatur, GA 30034

    Site contact: Ahmad Jingo

  • Medical Research Partners

    Ammon, ID 83406

    Site contact: 208-681-9070

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, IL 60640

    Site contact: 773-275-3500

  • Qualmedica Research, LLC

    Evansville, IN 47715

    Site contact: 812-205-2475

  • AMR Clinical

    Newton, KS 67114

    Site contact: 316-804-7304

  • Monroe Biomedical Research - Louisville

    Louisville, KY 40213

    Site contact: 502-515-5672

  • Skylight Health Research - Burlington

    Burlington, MA 01803

    Site contact: 781-653-4281

  • Care Access - Quincy

    Quincy, MA 02169

    Site contact: 877-791-0656

  • Ellipsis Research Group - Brooklyn - 7th Street

    Brooklyn, NY 11215

    Site contact: 347-422-0317

  • Rochester Clinical Research - Buffalo

    Buffalo, NY 14127

    Site contact: Rajiv Jain

  • NYC Research INC

    Long Island City, NY 11106

    Site contact: 516-574-9232

  • Rochester Clinical Research, LLC

    Rochester, NY 14609

    Site contact: 585-288-0890

  • Central States Research

    Tulsa, OK 74136

    Site contact: 918-645-5400

  • Keystone Clinical Studies

    Plymouth Meeting, PA 19462

    Site contact: Cameron Olezene

  • JCCT - Juno Bellaire Site

    Bellaire, TX 77401

    Site contact: 713-779-5494

  • Epic Medical Research - DeSoto

    DeSoto, TX 75115

    Site contact: 197-277-7695

  • Valley Institute of Research - Fort Worth

    Fort Worth, TX 76164

    Site contact: 817-625-7733

  • Care Access - Houston

    Houston, TX 77054

    Site contact: 877-791-0656

  • VIP Trials

    San Antonio, TX 78230

    Site contact: 210-569-2672

  • Endeavor Clinical Trials

    San Antonio, TX 78240

    Site contact: 518-428-6859

  • Consano Clinical Research, LLC

    Shavano Park, TX 78231

    Site contact: 210-545-4900

  • Texas Valley Clinical Research

    Weslaco, TX 78596

    Site contact: 956-431-8090

  • AMR Clinical

    South Jordan, UT 84095

    Site contact: Curtis Andrews

  • Charlottesville Medical Research

    Charlottesville, VA 22911

    Site contact: 434-817-2442

  • Paramount Clinical Research - Data Point Clinical Research

    Kirkland, WA 98034

    Site contact: 425-577-1107

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All weight loss studies in Alabama →
Efficacy and Safety of Eloralintide (LY3841136) in Participants… (NCT07353931) | Bored Studies